For 2025, J&J projects $90.9–$91.7 billion in sales
Johnson & Johnson (J&J) reported $22.52 billion in fourth-quarter sales, exceeding Wall Street estimates by 5.3%, driven by a 19% global rise in cancer drug sales. Its top-selling drug, Darzalex, generated $3 billion in sales, up 20.9% from a year ago.
However, its psoriasis treatment Stelara sales fell 14.7% due to biosimilar competition.
Adjusted earnings reached $2.04 per share, slightly beating expectations of $2.01 despite a 22-cent charge for its acquisition of medical device maker V-Wave.
J&J’s $14.6 billion acquisition of Intra-Cellular aims to strengthen its psychiatric drug portfolio but will impact 2024 earnings by 30–35 cents per share.
For 2025, J&J projects $90.9–$91.7 billion in sales and $10.75–$10.95 earnings per share, exceeding analysts’ forecasts.